Scleroderma News

As much as 43% of patients with systemic sclerosis demonstrate evidence of myopathy, while those with proximal weakness and higher creatine kinase exhibit worse function and survival, according to data.

Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.

Patients with higher levels of gamma-glutamyl transferase, and particularly men, demonstrate a significantly higher risk for systemic sclerosis, according to data published in Nature Scientific Reports.

Come the new year, a “mini” pill could have a massive impact in rheumatology care.

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.

SAN DIEGO — Shortness of breath, male sex, age and elevated inflammatory markers are all more predictive of new interstitial lung disease in systemic sclerosis than disease duration, according to data presented at ACR Convergence 2023.

The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.

The FDA has approved an investigational new drug application for Kyverna Therapeutics’ KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for diffuse cutaneous systemic sclerosis, according to a company press release.

The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.

The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with systemic sclerosis, according to a press release from its manufacturer.